This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

LSX USA Congress
Life Science Executive Partnering
Congress Sept 23-24, Forums Sept 22, 2026Hynes Convention Center, Boston, USA

Gregory Benning
Partner, Managing Director, Head of Investment Banking at Back Bay Life Science Advisors LLC
Speaker

Profile

Gregory Benning is a highly experienced M&A specialist with over 35 years of client advisory and transactional experience. He has managed and executed more than 350 M&A, divestiture and financing transactions, with proceeds totaling over $15B.

Before joining Back Bay in 2013, Mr. Benning was Head of M&A for the emerging growth investment bank, Adams Harkness, and a partner-level banker at the Boston-based investment bank, Tucker Anthony. He launched middle-market M&A practices for A.G. Edwards & Sons and Barrington Associates, both now part of Wells Fargo.

Mr. Benning is an acknowledged expert on M&A transaction markets, deal structures and acquisition finance, and has presented, spoken, and written for organizations including ACG Boston, the Angel Capital Association, Babson College, Boston University, Corporate Board Member, DKBIO, Ernst & Young, IBF's Venture Capital Summit, MassBIO, the Nantucket Conference, the National Association of Corporate Directors, Thomson Financial and YCombinator. He regularly participates in the professional development programs of several regional and national law firms, covering topics including embedded derivatives in M&A deal structures, earnouts and contingent payment structures and fairness opinion best practices.

Mr. Benning earned an MBA from the Harvard Graduate School of Business Administration and a BA in Public Policy Analysis from the University of Pennsylvania. He is a FINRA-licensed Series 24 General Securities Principal.

Agenda Sessions

  • The Role of Private Equity in Scaling Biopharma Companies

    9:35am